Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
10000
million yenWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2027 · Six months (cumulative) and full fiscal yearPrevious forecast published 14 May 2026Net SalesCumulative second-quarter results255,000→265,000million yen
+3.9%
Net SalesFull year535,000→545,000million yen
+1.9%
Operating profitCumulative second-quarter results23,000→25,000million yen
+8.7%
Operating profitFull year58,000→60,000million yen
+3.4%
Profit attributable to owners of the parentCumulative second-quarter results14,000→15,000million yen
+7.1%
Profit attributable to owners of the parentFull year36,000→37,000million yen
+2.8%
Net income per shareCumulative second-quarter results22.53→24.68yen and sen
+9.5%
Net income per shareFull year57.93→60.89yen and sen
+5.1%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
The forecasts are expected to exceed the previous forecasts due to strong equipment sales in the hematology field in the Americas during the first quarter, as well as foreign exchange rates trending weaker against the yen than assumed, among other factors.
Previous-period resultsSecond quarter (cumulative): net sales of ¥232,527 million, operating profit of ¥32,957 million, profit before tax of ¥29,955 million, interim profit attributable to owners of the parent of ¥19,019 million, and basic interim earnings per share of ¥30.50. Full year: net sales of ¥500,006 million, operating profit of ¥51,831 million, profit before tax of ¥49,051 million, profit attributable to owners of the parent of ¥35,457 million, and basic earnings per share of ¥56.89.
Dividend forecast revisionNo revision. No change from the information announced on 14 May 2026.
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Cumulative second-quarter results 255,000 / Full year 535,000 → Cumulative second-quarter results 265,000 / Full year 545,000（Cumulative second-quarter results 3.9% / Full year 1.9%） |
| Operating profit | Cumulative second-quarter results 23,000 / Full year 58,000 → Cumulative second-quarter results 25,000 / Full year 60,000（Cumulative second-quarter results 8.7% / Full year 3.4%） |
| Profit attributable to owners of the parent | Cumulative second-quarter results 14,000 / Full year 36,000 → Cumulative second-quarter results 15,000 / Full year 37,000（Cumulative second-quarter results 7.1% / Full year 2.8%） |
| Net income per share | Cumulative second-quarter results 22.53 / Full year 57.93 → Cumulative second-quarter results 24.68 / Full year 60.89 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months (cumulative) and full fiscal year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Second quarter (cumulative): net sales of ¥232,527 million, operating profit of ¥32,957 million, profit before tax of ¥29,955 million, interim profit attributable to owners of the parent of ¥19,019 million, and basic interim earnings per share of ¥30.50. Full year: net sales of ¥500,006 million, operating profit of ¥51,831 million, profit before tax of ¥49,051 million, profit attributable to owners of the parent of ¥35,457 million, and basic earnings per share of ¥56.89. |
| Reason for the revision | The forecasts are expected to exceed the previous forecasts due to strong equipment sales in the hematology field in the Americas during the first quarter, as well as foreign exchange rates trending weaker against the yen than assumed, among other factors. |
| Dividend forecast revision | No revision. No change from the information announced on 14 May 2026. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Ordinary incomeDetails and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is due to strong equipment sales in the hematology field in the Americas during the first quarter, as well as foreign exchange rates trending weaker against the yen than assumed, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.